Home Members Tools Credit Cards
   

RIGL Stock Quote and Technical Analysis

Portfolios Markets Resources
  Symbol List
Rigel Pharmaceuticals, Inc. (RIGL)
▼ 3.24 (-0.03) -0.92%
Open: 3.31
High: 3.31
Low: 3.13
Afterhours: N/A - N/A
Volume: 343533
8/1/2014 4:00pm
 
Interactive Chart
EPS: -0.981 (Current Year Estimated: -1.03)
Dividend: N/A
P/E: N/A

Technicals:
52 Week Range: 2.31 - 5.00
50 Day Moving Average: 3.5523
200 Day Moving Average: 3.4835
Pivot Point (Next Trading Session): 3.23

Login or signup free to Add "RIGL" to your portfolio

Resources:

News:


Rigel Pharmaceuticals Starts Fostamatinib Late Stage Program
Thu, 17 Jul 2014 19:45:06 GMT


Rigel Initiates Phase 3 Studies of Fostamatinib in ITP
Wed, 16 Jul 2014 13:24:13 GMT
[at noodls] - SOUTH SAN FRANCISCO, Calif., July 16, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the initiation of a Phase 3 clinical program for its oral SYK inhibitor, fostamatinib, ...

Rigel Initiates Phase 3 Studies of Fostamatinib in ITP
Wed, 16 Jul 2014 12:35:00 GMT
[PR Newswire] - SOUTH SAN FRANCISCO, Calif., July 16, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (RIGL) today announced the initiation of a Phase 3 clinical program for its oral SYK inhibitor, fostamatinib, in patients with ITP (immune thrombocytopenic purpura). The focus of these clinical studies is to evaluate the potential of fostamatinib to increase the platelet counts of patients with chronic ITP. Fostamatinib may provide a novel therapeutic for the underlying cause of this autoimmune disease of the blood. "Based on our extensive clinical experience with this product candidate, which includes more than 4,500 patient-years of data, we hope to demonstrate that fostamatinib can provide a new treatment option for patients with chronic ITP," said James M. Gower, chairman and chief executive officer of Rigel.

Rigel Pharmaceuticals initiates Phase 3 studies of fostamatinib in ITP
Wed, 16 Jul 2014 11:31:59 GMT


Rigel to Present at Jefferies 2014 Global Healthcare Conference
Thu, 29 May 2014 11:30:00 GMT
[PR Newswire] - SOUTH SAN FRANCISCO, Calif., May 29, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled ...

RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a V
Tue, 27 May 2014 20:16:20 GMT


RIGEL PHARMACEUTICALS INC Financials
Wed, 14 May 2014 17:04:25 GMT


RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
Wed, 07 May 2014 20:45:43 GMT


RIGEL PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
Wed, 07 May 2014 17:47:55 GMT


Rigel Announces First Quarter 2014 Financial Results
Wed, 07 May 2014 11:30:00 GMT
[PR Newswire] - SOUTH SAN FRANCISCO, Calif., May 7, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the first quarter ended March 31, 2014. For the first quarter of ...

Q1 2014 Rigel Pharmaceuticals Inc. Earnings Release - Before Market Open
Wed, 07 May 2014 11:07:06 GMT


Rigel Announces Webcast of Investor Day on May 6, 2014
Wed, 30 Apr 2014 11:30:00 GMT
[PR Newswire] - SOUTH SAN FRANCISCO, Calif., April 30, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will host an Investor Day on Tuesday, May 6, 2014 from 9:30 a.m. to 12:00 ...

Is Rigel Pharmaceuticals (RIGL) Stock a Solid Choice Right Now?
Fri, 11 Apr 2014 11:00:13 GMT


RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers
Fri, 21 Mar 2014 20:16:25 GMT


Why VAALCO Energy, Rigel Pharmaceuticals, and Companhia Siderurgica Nacional Are Today's 3 Best Stocks
Fri, 14 Mar 2014 21:16:14 GMT


Rigel (RIGL) Worth Watching: Stock Rises 10.2%
Fri, 07 Mar 2014 12:37:07 GMT


Why Rigel Pharmaceuticals, Inc. Shares Popped
Thu, 06 Mar 2014 18:51:59 GMT


Top Stories in Biotech This Morning: Pluristem Therapeutics, Inc, Rigel Pharmaceuticals, Inc. and Sangamo Biosciences, Inc.
Thu, 06 Mar 2014 13:49:57 GMT


Rigel Rises on Narrower Q4 Loss
Thu, 06 Mar 2014 13:40:06 GMT


Rigel Announces Publication of R118 AMPK Activator Research
Thu, 06 Mar 2014 13:15:23 GMT
[at noodls] - SOUTH SAN FRANCISCO, Calif., March 6, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the American Journal of Physiology has published recent research results with ...


All Company News is Powered by Yahoo! Finance

 

 

 

Credit Cards | Finance Social Network | Credit Card Reviews | Markets
About Us | FG on the Web | Sitemap | Privacy | Terms | Contact


Copyright © 2014 Finance Globe. All rights reserved.